The Library Derived 4554W Peptide Inhibits Primary Nucleation of α-Synuclein.
Parkinson’s disease
amyloid aggregation
lipid vesicles
peptide
α-Synuclein
Journal
Journal of molecular biology
ISSN: 1089-8638
Titre abrégé: J Mol Biol
Pays: Netherlands
ID NLM: 2985088R
Informations de publication
Date de publication:
04 12 2020
04 12 2020
Historique:
received:
08
07
2020
revised:
02
11
2020
accepted:
05
11
2020
pubmed:
14
11
2020
medline:
5
3
2021
entrez:
13
11
2020
Statut:
ppublish
Résumé
Aggregation of α-Synuclein (αS) is widely regarded as a key factor in neuronal cell death, leading to a wide range of synucleinopathies, including Parkinson's Disease. Development of therapeutics has therefore focused on inhibiting aggregation of αS into toxic forms. One such inhibitor, based on the preNAC region αS
Identifiants
pubmed: 33186583
pii: S0022-2836(20)30624-0
doi: 10.1016/j.jmb.2020.11.005
pii:
doi:
Substances chimiques
Amyloid
0
Peptides
0
Protein Aggregates
0
SNCA protein, human
0
alpha-Synuclein
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
166706Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: JMM is an advisor to Sapience Therapeutics. There are no other financial or commercial conflicts to declare.